Vutrisiran can improve and maintain functional capacity and quality of life in patients with transthyretin amyloidosis with ...

March 25, 2025 – The FDA has approved a new treatment for adults with a life-threatening heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM). ATTR-CM is a rare but serious ...

Vutrisiran improved mortality and recurrent CV risks independent of disease severity and improved several other endpoints for ...

Opens in a new tab or window Gene-silencing therapy vutrisiran (Amvuttra) graduated to a broad indication in treatment of transthyretin amyloidosis cardiomyopathy, as Alnylam Pharmaceuticals ...

Amvuttra is now approved in the US to treat both cardiomyopathy and polyneuropathy manifestations of ATTR amyloidosis.

The Food and Drug Administration (FDA) has approved Amvuttra ® (vutrisiran) for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM ...

Despite growing competition in the transthyretin amyloid cardiomyopathy (ATTR-CM) field, Alnylam is hoping its RNA interference approach can set it apart from its peers. And now, the Massachusetts ...

has approved a supplemental new drug application for vutrisiran for the treatment of wild-type or hereditary transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) to reduce cardiovascular death ...

Intellia Therapeutics has commenced subject dosing in the Phase III MAGNITUDE-2 trial of nexiguran ziclumeran (nex-z) for ...